Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study

Area of Science:

• Cardiology
• Pharmacology
• Biochemistry

Background:

• Low high density lipoprotein (HDL) cholesterol and elevated triglycerides increase coronary heart disease (CHD) risk.
• Therapeutic benefits of increasing HDL and lowering triglycerides for reducing myocardial infarctions and mortality remain unclear.
• Secondary prevention in CHD patients requires further investigation into lipid modification therapies.

Purpose of the Study:

• To evaluate the efficacy of bezafibrate in reducing cardiovascular events in patients with CHD.
• To assess the impact of bezafibrate on lipid profiles, including HDL cholesterol and triglycerides.
• To examine bezafibrate's effect on plasma fibrinogen levels.

Main Methods:

• The Bezafibrate Infarction Prevention (BIP) study was a randomized, placebo-controlled trial.
• 3122 patients with CHD were randomized to receive bezafibrate retard (400 mg daily) or placebo.
• Patients had specific criteria for total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides at baseline.

Main Results:

• Bezafibrate significantly lowered plasma fibrinogen in addition to its lipid-modifying effects.
• Baseline demographic, clinical, and biochemical characteristics of the study population are presented.
• A comparison with other secondary prevention studies of lipid modification in CHD patients is provided.

Conclusions:

• The study provides baseline data for a large cohort of CHD patients undergoing lipid modification therapy.
• Bezafibrate's multifaceted effects on lipids and fibrinogen warrant further investigation in secondary CHD prevention.
• The findings contribute to understanding lipid modification strategies in patients with established coronary heart disease.